SCHEMBL2625567

SCHEMBL2625567

CC(C)NC(=O)NCC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.47
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 3/20 0.33
EPHX2 P34913 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
CA9 Q16790 1/20 0.33
MAPT P10636 1/20 0.33
CPB2 Q96IY4 1/20 0.33
FAAH O00519 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12449180 0.84 EPHX1 (0.46) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL23437494 0.81 EPHX1 (0.47) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL19068846 0.80 EPHX1 (0.46) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL2824552 0.80 BCHE (0.36) EPHX1EPHX2HSD17B10SMN1; SMN2BCHE
SCHEMBL19703744 0.78 EPHX1 (0.53) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL20686302 0.78 EPHX1 (0.41) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL24449236 0.78 EPHX1 (0.41) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL14011283 0.76 EPHX1 (0.48) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL29307979 0.74 EPHX1 (0.44) EPHX1ALDH1A1MEN1KMT2ALMNA
SCHEMBL860139 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
WO-2005030796-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE SCHERING CORPORATION (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 TBK1, NFKBIA, IKBKB EPHX1 2711/4885ALDH1A1 4626/4885MEN1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.